Cell therapy companies have been rapidly populating over the past few years, making the cell therapy market a high-value, fast-growth market. Key drivers for the market include high rates of cell therapy clinical trials, accelerated pathways for cell therapy product approvals, new technologies to support cell therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
Current market segments include:
- Stem cell therapeutics
- Direct reprogramming
- Dendritic cell immunotherapies
- And more
Additionally, the market gained recent momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta).
These historic events demonstrate to investors, the public and funding providers alike that cell therapy is a market that has emerged, no longer one that is evolving in the future. Today, there are nearly 40 companies developing redirected T cells or NK cells for therapeutic use. There are nearly 70 companies developing stem cell therapeutics (45% of all cell therapy companies). Finally, direct cell reprogramming is gaining popularity as a therapeutic strategy, because of its safety and efficacy advantages.
Because of this rapid market growth, BioInformant has released a global database featuring 150+ cell therapy companies worldwide. It was originally developed in-house for our own purposes, but we have had more and more clients requesting access to it. For this reason, we updated and expanded it with additional company details. Now, we have officially launched it to the public.